Literature DB >> 18467657

Interleukin 21: a cytokine/cytokine receptor system that has come of age.

Warren J Leonard1, Rong Zeng, Rosanne Spolski.   

Abstract

Interleukin-21 (IL-21) and its receptor represent the sixth cytokine system whose actions were recognized to require the common cytokine receptor gamma chain. IL-21 is produced by activated CD4+ T cells, natural killer T cells, and follicular T helper cells and has actions on a range of lymphohematopoietic lineages. Among its many effects, IL-21 serves a critical role for immunoglobulin production and terminal B cell differentiation, acts as a T cell comitogen and can drive the expansion of CD8+ T cells, can negatively regulate dendritic cell function and plays an essential role in the differentiation of Th17 cells. Importantly, IL-21 is implicated in the pathogenesis of autoimmunity and exhibits potent actions as an antitumor agent. The ability to regulate and manipulate the actions of IL-21, therefore, has important implications for immunoregulation and the therapy of human disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18467657      PMCID: PMC2493068          DOI: 10.1189/jlb.0308149

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  62 in total

1.  Calcium-dependent activation of interleukin-21 gene expression in T cells.

Authors:  Hyoung-Pyo Kim; Lisa L Korn; Ana M Gamero; Warren J Leonard
Journal:  J Biol Chem       Date:  2005-05-06       Impact factor: 5.157

2.  An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma.

Authors:  Ian D Davis; Birte K Skrumsager; Jonathan Cebon; Theo Nicholaou; John W Barlow; Niels Peter Hundahl Moller; Kresten Skak; Dorthe Lundsgaard; Klaus Stensgaard Frederiksen; Peter Thygesen; Grant A McArthur
Journal:  Clin Cancer Res       Date:  2007-06-15       Impact factor: 12.531

3.  IL-21 administration into the nostril alleviates murine allergic rhinitis.

Authors:  Yayoi Hiromura; Tsunao Kishida; Hiroshi Nakano; Takemitsu Hama; Jiro Imanishi; Yasuo Hisa; Osam Mazda
Journal:  J Immunol       Date:  2007-11-15       Impact factor: 5.422

Review 4.  Interleukin-21: basic biology and implications for cancer and autoimmunity.

Authors:  Rosanne Spolski; Warren J Leonard
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

5.  Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma.

Authors:  John A Thompson; Brendan D Curti; Bruce G Redman; Shailender Bhatia; Jeffrey S Weber; Sanjiv S Agarwala; Eric L Sievers; Steven D Hughes; Todd A DeVries; Diana F Hausman
Journal:  J Clin Oncol       Date:  2008-03-17       Impact factor: 44.544

6.  Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus.

Authors:  A H Sawalha; K M Kaufman; J A Kelly; A J Adler; T Aberle; J Kilpatrick; E K Wakeland; Q-Z Li; A E Wandstrat; D R Karp; J A James; J T Merrill; P Lipsky; J B Harley
Journal:  Ann Rheum Dis       Date:  2007-08-24       Impact factor: 19.103

7.  Essential autocrine regulation by IL-21 in the generation of inflammatory T cells.

Authors:  Roza Nurieva; Xuexian O Yang; Gustavo Martinez; Yongliang Zhang; Athanasia D Panopoulos; Li Ma; Kimberly Schluns; Qiang Tian; Stephanie S Watowich; Anton M Jetten; Chen Dong
Journal:  Nature       Date:  2007-06-20       Impact factor: 49.962

8.  IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways.

Authors:  Liang Zhou; Ivaylo I Ivanov; Rosanne Spolski; Roy Min; Kevin Shenderov; Takeshi Egawa; David E Levy; Warren J Leonard; Dan R Littman
Journal:  Nat Immunol       Date:  2007-06-20       Impact factor: 25.606

9.  IL-21 induces inhibitor of differentiation 2 and leads to complete abrogation of anaphylaxis in mice.

Authors:  Tsunao Kishida; Yayoi Hiromura; Masaharu Shin-Ya; Hidetsugu Asada; Hiroko Kuriyama; Manabu Sugai; Akira Shimizu; Yoshifumi Yokota; Takemitsu Hama; Jiro Imanishi; Yasuo Hisa; Osam Mazda
Journal:  J Immunol       Date:  2007-12-15       Impact factor: 5.422

Review 10.  Interleukin 21: combination strategies for cancer therapy.

Authors:  Kresten Skak; Michael Kragh; Diana Hausman; Mark J Smyth; Pallavur V Sivakumar
Journal:  Nat Rev Drug Discov       Date:  2008-03       Impact factor: 84.694

View more
  50 in total

1.  Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes.

Authors:  Keli L Hippen; Christoph Bucher; Dawn K Schirm; Amanda M Bearl; Ty Brender; Kathy A Mink; Kimberly S Waggie; Regis Peffault de Latour; Anne Janin; Julie M Curtsinger; Stacey R Dillon; Jeffrey S Miller; Gerard Socie; Bruce R Blazar
Journal:  Blood       Date:  2011-11-10       Impact factor: 22.113

2.  Interleukin-21 and cellular activation concurrently induce potent cytotoxic function and promote antiviral activity in human CD8 T cells.

Authors:  Anita Parmigiani; Maria F Pallin; Helena Schmidtmayerova; Mathias G Lichtenheld; Savita Pahwa
Journal:  Hum Immunol       Date:  2010-10-25       Impact factor: 2.850

Review 3.  Clinically feasible approaches to potentiating cancer cell-based immunotherapies.

Authors:  V I Seledtsov; A G Goncharov; G V Seledtsova
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Opposing roles of STAT1 and STAT3 in IL-21 function in CD4+ T cells.

Authors:  Chi-Keung Wan; Allison B Andraski; Rosanne Spolski; Peng Li; Majid Kazemian; Jangsuk Oh; Leigh Samsel; Phillip A Swanson; Dorian B McGavern; Elizabeth P Sampaio; Alexandra F Freeman; Joshua D Milner; Steven M Holland; Warren J Leonard
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-13       Impact factor: 11.205

5.  Differential effects of IL-2 and IL-21 on expansion of the CD4+ CD25+ Foxp3+ T regulatory cells with redundant roles in natural killer cell mediated antibody dependent cellular cytotoxicity in chronic lymphocytic leukemia.

Authors:  Aruna Gowda; Asha Ramanunni; Carolyn Cheney; Darlene Rozewski; Wayne Kindsvogel; Amy Lehman; David Jarjoura; Michael Caligiuri; John C Byrd; Natarajan Muthusamy
Journal:  MAbs       Date:  2010-01-08       Impact factor: 5.857

6.  Olf1/EBF associated zinc finger protein interfered with antinuclear antibody production in patients with systemic lupus erythematosus.

Authors:  Xuebing Feng; Rongliang Li; Jing Huang; Huayong Zhang; Lina Zhu; Bingzhu Hua; Betty P Tsao; Lingyun Sun
Journal:  Arthritis Res Ther       Date:  2010-04-01       Impact factor: 5.156

7.  The Production IL-21 and VEGF in UVB-irradiated Human Keratinocyte Cell Line, HaCaT.

Authors:  Hyemin Kim; Jae Seung Kang; Wang Jae Lee
Journal:  Immune Netw       Date:  2010-04-30       Impact factor: 6.303

Review 8.  Shaping successful and unsuccessful CD8 T cell responses following infection.

Authors:  Maureen A Cox; Allan J Zajac
Journal:  J Biomed Biotechnol       Date:  2010-03-31

9.  Interleukin-21 is required for the development of type 1 diabetes in NOD mice.

Authors:  Andrew P R Sutherland; Tom Van Belle; Andrea L Wurster; Akira Suto; Monia Michaud; Dorothy Zhang; Michael J Grusby; Matthias von Herrath
Journal:  Diabetes       Date:  2009-02-10       Impact factor: 9.461

10.  Upregulated IL-21 and IL-21 receptor expression is involved in experimental autoimmune uveitis (EAU).

Authors:  Lan Liu; Yongfeng Xu; Jianyong Wang; Huiyan Li
Journal:  Mol Vis       Date:  2009-12-31       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.